Current treatment status-Undergoing active treatment-Progressive despite several lines of treatment - Page 4 of 24 Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-Progressive despite several lines of treatment Posts on Medivizor

Copanlisib plus rituximab improves survival in patients with relapsed painless non-Hodgkin lymphoma.

Copanlisib plus rituximab improves survival in patients with relapsed painless non-Hodgkin lymphoma.

Posted by on May 22, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study reported the effectiveness and safety outcomes of copanlisib (Aliqopa) and rituximab (Rituxan) combination for the treatment of patients with relapsed indolent (painless) non-Hodgkin lymphoma (NHL). The data showed that this combination improved the outcomes of these patients with manageable side effects. Some background...

Read More

Is autologous stem cell transplantation after anti-PD-1 therapy an effective treatment for patients with relapsed or refractory Hodgkin lymphoma?

Is autologous stem cell transplantation after anti-PD-1 therapy an effective treatment for patients with relapsed or refractory Hodgkin lymphoma?

Posted by on May 15, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell The authors assessed the effectiveness of autologous stem cell transplantation (ASCT) after anti-PD-1 therapy for the treatment of patients with high-risk relapsed/refractory (r/r) Hodgkin lymphoma (HL). The study found that ASCT after anti-PD-1 therapy had very good outcomes in patients with r/r HL. Some background Standard...

Read More

Searching for patients with solid tumors with abnormal genetic changes to trial an experimental medication

Searching for patients with solid tumors with abnormal genetic changes to trial an experimental medication

Posted by on Apr 30, 2021 in Melanoma | 0 comments

In a nutshell This study is searching for participants with advanced solid tumors including melanoma to examine the safety and effectiveness of experimental drug avapritinib (Ayvakit). The main outcomes to be measured are the response to treatment and side effects. This trial is being conducted in Texas, US. The details Some cancers grow as a...

Read More

Searching for patients with solid tumors with abnormal genetic changes to trial an experimental medication

Searching for patients with solid tumors with abnormal genetic changes to trial an experimental medication

Posted by on Apr 30, 2021 in Lung cancer | 0 comments

In a nutshell This study is searching for participants with advanced solid tumors including lung cancer to examine the safety and effectiveness of experimental drug avapritinib (AYVAKIT). The main outcomes to be measured are the response to treatment and side effects. This trial is being conducted in Texas, US. The details Some cancers grow as a...

Read More

Searching for patients with solid tumors with abnormal genetic changes to trial an experimental medication

Searching for patients with solid tumors with abnormal genetic changes to trial an experimental medication

Posted by on Apr 30, 2021 in Colorectal cancer | 0 comments

In a nutshell This study is searching for participants with advanced solid tumors including colorectal cancer to examine the safety and effectiveness of experimental drug avapritinib (AYVAKIT). The main outcomes to be measured are the response to treatment and side effects. This trial is being conducted in Texas, US. The details Some cancers grow as a...

Read More

Evaluating pirtobrutinib for the treatment on B cell leukemia/lymphoma

Evaluating pirtobrutinib for the treatment on B cell leukemia/lymphoma

Posted by on Apr 30, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study tested the safety and effectiveness of pirtobrutinib (LOXO-305) in the treatment of patients with B cell leukemia/lymphoma. The authors found that pirtobrutinib was safe and had promising effectiveness in these patients. Some background B cells are a type of cell of the immune system. Some lymphomas and leukemias such as...

Read More

How effective and safe is glofitamab for the treatment of patients with relapsed or refractory B-cell lymphoma?

How effective and safe is glofitamab for the treatment of patients with relapsed or refractory B-cell lymphoma?

Posted by on Apr 25, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to evaluate the safety, optimal dosage, and effectiveness of glofitamab (RO7082859) for the treatment of patients with relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL). The authors concluded that glofitamab treatment on its own or in combination with other immunotherapies is safe and effective in these...

Read More

Idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia in a real life setting

Idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia in a real life setting

Posted by on Apr 24, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the effectiveness of idelalisib (Zydelig) and rituximab (Rituxan) in patients with relapsed/refractory (r/r) chronic lymphocytic leukemia (CLL) in a real-life setting.  This study concluded that this treatment in a real-life setting was just as effective as in a clinical trial...

Read More

Is VD-PACE and immunotherapy a good salvage therapy for relapsed/refractory multiple myeloma?

Is VD-PACE and immunotherapy a good salvage therapy for relapsed/refractory multiple myeloma?

Posted by on Apr 11, 2021 in Multiple Myeloma | 0 comments

In a nutshell The aim of this study was to evaluate if the VD-PACE (bortezomib, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, etoposide) regimen in combination with immunotherapy was effective as a salvage therapy for patients with relapsed or refractory (r/r) multiple myeloma (MM). The study found this salvage therapy option...

Read More

How effective is umbralisib as treatment for patients with relapsed or refractory low-grade lymphoma?

How effective is umbralisib as treatment for patients with relapsed or refractory low-grade lymphoma?

Posted by on Apr 11, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The authors assessed the safety and effectiveness of umbralisib (Ukoniq) in patients with relapsed or refractory (r/r) indolent (low-grade) non-Hodgkin lymphoma (iNHL).   The study concluded that umbralisib was well tolerated and effective for patients with r/r iNHL. Some background iNHL is a slow-growing cancer of...

Read More

Comparing ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukemia

Comparing ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukemia

Posted by on Apr 11, 2021 in Leukemia | 0 comments

In a nutshell This study investigated the safety and effectiveness of adding ublituximab (TG-1101) to ibrutinib (Imbruvica) treatment for patients with relapsed or refractory (r/r) chronic lymphocytic leukemia (CLL). The data showed that adding ublituximab to ibrutinib significantly improved the overall response rate compared to ibrutinib alone...

Read More

How effective is involved field radiotherapy after autologous hematopoietic stem-cell transplantation in patients with high-risk relapsed/refractory lymphoma?

How effective is involved field radiotherapy after autologous hematopoietic stem-cell transplantation in patients with high-risk relapsed/refractory lymphoma?

Posted by on Apr 4, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The authors assessed the safety and efficacy of involved-field radiotherapy (IFRT) after autologous hematopoietic stem-cell transplantation (ASCT) in patients with high-risk relapsed/refractory (r/r) lymphoma. The study found that IFRT given soon after ASCT provided durable responses and was well tolerated in these patients. Some...

Read More